Transfusion Medicine Reviews
Volume 23, Issue 3 , Pages 189-204 , July 2009

Antigen Loss From Antibody-Coated Red Blood Cells

  • James C. Zimring

      Affiliations

    • Corresponding Author InformationAddress reprint request to James C. Zimring, MD, PhD, Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Woodruff Memorial Building Suite 7301, 101 Woodruff Cir, Atlanta, GA 30322.
    • ,
  • Chantel M. Cadwell
    • ,
  • Steven L. Spitalnik

References 

  1. Reid ME, Lomas-Francis C. The blood group antigen facts book. 2nd ed.. Amsterdam: Elsevier Academic Press; 2004;
  2. Bosco AM, Xenocostas A, Kinney J, et al. An auto-anti-Kpb IgM that simulates antigen-suppression. Transfusion. 2009;49:750–756
  3. Seyfried H, Gorska B, Maj S, et al. Apparent depression of antigens of the Kell blood group system associated with autoimmune acquired haemolytic anaemia. Vox Sang. 1972;23:528–536
  4. Beck ML, Marsh WL, Pierce SR, et al. Auto anti-Kpb associated with weakened antigenicity in the Kell blood group system: A second example. Transfusion. 1979;19:197–202
  5. Brendel WL, Issitt PD, Moore RE, et al. Temporary reduction of red cell Kell system antigen expression and transient production of anti-Kpb in a surgical patient. Biotest Bull. 1985;2:201–206
  6. Marsh WL, Oyen R, Alicea E, et al. Autoimmune hemolytic anemia and the Kell blood groups. Am J Hematol. 1979;7:155–162
  7. Vengelen-Tyler V, Gonzalez B, Garratty G, et al. Acquired loss of red cell Kell antigens. Br J Haematol. 1987;65:231–234
  8. Williamson LM, Poole J, Redman C, et al. Transient loss of proteins carrying Kell and Lutheran red cell antigens during consecutive relapses of autoimmune thrombocytopenia. Br J Haematol. 1994;87:805–812
  9. Koscielak J. Session on blood group substances and red cell membrane receptors. Vox Sang. 1980;39:289
  10. van't Veer MB, van Wieringen PM, van Leeuwen I, et al. A negative direct antiglobulin test with strong IgG red cell autoantibodies present in the serum of a patient with autoimmune haemolytic anaemia. Br J Haematol. 1981;49:383–386
  11. Issitt PD, Gruppo RA, Wilkinson SL, et al. Atypical presentation of acute phase, antibody-induced haemolytic anaemia in an infant. Br J Haematol. 1982;52:537–543
  12. Issitt PD, Wilkinson SL, Gruppo RA. Depression of Rh antigen expression in antibody-induced haemolytic anaemia. Br J Haematol. 1983;53:688
  13. Ganly PS, Laffan MA, Owen I, et al. Auto-anti-Jka in Evans' syndrome with negative direct antiglobulin test. Br J Haematol. 1988;69:537–539
  14. Issitt PD, Obarski G, Hartnett PL, et al. Temporary suppression of Kidd system antigen expression accompanied by transient production of anti-Jk3. Transfusion. 1990;30:46–50
  15. Powers A, Mohammed M, Uhl L, et al. Apparent nonhemolytic alloantibody-induced red-cell antigen loss from transfused erythrocytes. Blood. 2007;109:15
  16. Beattie KM, Sigmund KE. A Ge-like autoantibody in the serum of a patient receiving gold therapy for rheumatoid arthritis. Transfusion. 1987;27:54–57
  17. Daniels GL, Reid ME, Anstee DJ, et al. Transient reduction in erythrocyte membrane sialoglycoprotein beta associated with the presence of elliptocytes. Br J Haematol. 1988;70:477–481
  18. Chown B, Kaita H, Lowen B, et al. Transient production of anti-LW by LW-positive people. Transfusion. 1971;11:220–222
  19. Giles CM, Lundsgaard A. A complex serological investigation involving LW. Vox Sang. 1967;13:406–416
  20. Perkins HA, McIlroy M, Swanson J, et al. Transient LW-negative red blood cells and anti-LW in a patient with Hodgkin's disease. Vox Sang. 1977;33:299–303
  21. Mannessier L, Rouger P, Johnson CL, et al. Acquired loss of red-cell Wj antigen in a patient with Hodgkin's disease. Vox Sang. 1986;50:240–244
  22. Banks J, Poole J, Prowse C, et al. Transient loss of Cromer antigens and anti-IFC in a patient with chronic lymphatic leukaemia. Vox Sang. 2004;87:S37–S38
  23. Matthes T, Tullen E, Poole J, et al. Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC. Transfusion. 2002;42:1448–1457
  24. Yazer MH, Judd WJ, Davenport RD, et al. Case report and literature review: Transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem. Transfusion. 2006;46:1537–1542
  25. Cadwell CM, Zimring JC. Cross-linking induces non-haemolytic antigen-loss from transfused red blood cells: A potential role for rheumatoid factor. Vox Sang. 2008;95:159–162
  26. Mack DA, Beum PV, Lindorfer MA, et al. The shaving reaction is facilitated through trogocytosis: concerted transfer of both rituximab (RTX) and membrane dye PKH26 from B lymphocytes to macrophages is demonstrable by flow cytometry, fluorescence microscopy, and high resolution digital imaging in a flow cytometric environment. Blood. 2006;108:594a
  27. Poole J, Reid ME, Banks J, et al. Serological and immunochemical specificity of a human autoanti-Gerbich–like antibody. Vox Sang. 1990;58:287–291
  28. Beum PV, Kennedy AD, Li Y, et al. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. J Immunol Methods. 2004;294:37–42
  29. McGinniss MH, Lieberman R, Holland PV. The Jkb red cell antigen and gram-negative organisms (abstract). Transfusion. 1979;19:663
  30. McGinniss MH, MacLowry JD, Holland PV. Acquisition of K:1-like antigen during terminal sepsis. Transfusion. 1984;24:28–30
  31. Miescher S, Spycher MO, Amstutz H, et al. A single recombinant anti-RhD IgG prevents RhD immunization: Association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood. 2004;103:40284035
  32. Schirmer DA, Song SC, Baliff JP, et al. Mouse models of IgG- and IgM-mediated hemolysis. Blood. 2007;109:3099–3107
  33. Campbell-Lee SA, Liu J, Velliquette RW, et al. The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice. Transfusion. 2006;46:1682–1688
  34. Zimring JC, Hair GA, Chadwick TE, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood. 2005;106:1105–1112
  35. Zimring JC, Cadwell CM, Chadwick TE, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood. 2007;110:2201–2208
  36. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. 1980;152:20–30
  37. Nelson RA. The immune-adherence phenomenon; a hypothetical role of erythrocytes in defence against bacteria and viruses. Proc R Soc Med. 1956;49:55–58
  38. Nelson RA. The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science. 1953;118:733–737
  39. Cosio FG, Shen XP, Birmingham DJ, et al. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol. 1990;145:4198–4206
  40. Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest. 1983;71:236–247
  41. Davies KA, Hird V, Stewart S, et al. A study of in vivo immune complex formation and clearance in man. J Immunol. 1990;144:4613–4620
  42. Nardin A, Lindorfer MA, Taylor RP. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells?. Mol Immunol. 1999;36:827–835
  43. Moll S, Miot S, Sadallah S, et al. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int. 2001;59:160–168
  44. Bertram JH, Gill PS, Levine AM, et al. Monoclonal antibody T101 in T cell malignancies: A clinical, pharmacokinetic, and immunologic correlation. Blood. 1986;68:752–761
  45. Letvin NL, Ritz J, Guida LJ, et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood. 1985;66:961–966
  46. Miller RA, Maloney DG, McKillop J, et al. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood. 1981;58:78–86
  47. Shawler DL, Johnson DE, McCallister TJ, et al. Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101. Clin Immunol Immunopath. 1988;47:219–229
  48. Shawler DL, Miceli MC, Wormsley SB, et al. Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res. 1984;44:5921–5927
  49. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280–3288
  50. Li Y, Williams ME, Cousar JB, et al. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007;179:4263–4271
  51. Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176:2600–2609
  52. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol. 2008;181:2916–2924
  53. Beum PV, Mack DA, Pawluczkowycz AW, et al. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol. 2008;181:8120–8132
  54. Griffin FM, Griffin JA, Silverstein SC. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med. 1976;144:788–809
  55. Boylan B, Chen H, Rathore V, et al. Anti-GPVI–associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004;104:1350–1355
  56. Massberg S, Gawaz M, Gruner S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. 2003;197:41–49
  57. Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001;193:459–469
  58. Schulte V, Rabie T, Prostredna M, et al. Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood. 2003;101:3948–3952
  59. Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol. 1992;22:2449–2452
  60. Sophianos D, Tzartos SJ. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera. J Autoimmun. 1989;2:777–789
  61. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol. 1985;134:2343–2349
  62. Kao I, Drachman DB. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977;196:527–529

PII: S0887-7963(09)00028-5

doi: 10.1016/j.tmrv.2009.03.002

Transfusion Medicine Reviews
Volume 23, Issue 3 , Pages 189-204 , July 2009

Article Tools